
Am Fam Physician. 2022;105(6):online
Clinical Question
Bottom Line
Synopsis
The investigators identified adults, 45 years and older, with symptomatic heart failure, elevated NT-proBNP levels, NYHA class II through IV, a left ventricular ejection fraction of greater than 40%, and an impaired health-related quality of life as measured by a standard scoring tool. Patients taking an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) at baseline were required to have a history of hypertension. Eligible participants (N = 2,566) were initially assigned to one of three strata based on medication prescribed by their treating clinician: ACE inhibitor (n = 1,066), ARB (n = 1,174), or no RAS inhibitor (n = 326). Within each stratum, patients randomly received (concealed allocation assignment) sacubitril/valsartan or the background medication (i.e., ACE inhibitor, ARB, or placebo/no RAS inhibitor). Clinicians were instructed to up-titrate within four weeks to the maximally tolerated doses. Patients, clinicians, and individuals assessing outcomes remained masked to treatment group assignment. Complete follow-up occurred for more than 99% of patients at 24 weeks.
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available